OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

Impact · against what's priced in

OmniAb is seeing accelerated commercial adoption of its technology platform, with new program additions significantly outpacing 2024 rates. This suggests a stronger-than-previous growth trajectory for partner acquisition and future revenue potential.

OABI+0.30: No priced-in read yet
In context: The company's report that new program additions this year have significantly outpaced last year's rate indicates a tangible acceleration in platform adoption.
Read from the article alone

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

earnings▲30%
biotech▲23%
pharmaceuticals
OABI
financial results

Top 2 movers · tap to explore

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

What matters in this story

How each ticker is affected

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

What matters in this story

How each ticker is affected

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

Track these names every morning.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

What matters in this story

How each ticker is affected

Next reads from the same story arc

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights

What matters in this story

How each ticker is affected

Next reads from the same story arc

Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder

Track these names every morning.

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026

Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.